Molecular diagnostics for tuberculosis

Pathology

Volumn 47, Issue 3, 2015, Pages 250-256

  Noor, K M ^a,b   Shephard, L ^a   Bastian, I ^a  

^a Rundle Mall   (Australia)

^b Politeknik Sultan Abdul Halim mu'Adzam Shah (POLIMAS)   (Malaysia)

Author keywords

diagnosis; DNA; molecular diagnostic techniques; sequence analysis; tuberculosis

Indexed keywords

HUMAN; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; TRENDS; TUBERCULOSIS;

HUMANS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR DIAGNOSTIC TECHNIQUES; TUBERCULOSIS;

EID: 84949808162     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000232     Document Type: Article

References (45)

1. 1. World Health Organization. Global tuberculosis report 2014. Geneva: WHO, 2014. WHO/HTM/TB/2014.08. http://www.who.int/tb/publications/global_report/en/.
2. ®MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6 (2011), 1067–1082.
3. rd edition. Geneva: WHO, 2014. http://www.unitaid.eu/images/marketdynamics/publications/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf.
4. 4. World Heath Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) – policy statement. Geneva: WHO, 2008. http://www.who.int/tb/features_archive/policy_statement.pdf.
5. 5. Rossau, R., Traore, H., De Beenhouwer, H., et al. Evaluation ofthe INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 10 (1997), 2093–2098.
6. 6. Palomino, J.C., Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 56 (2009), 103–111.
7. 7. Yuen, L.K.W., Ross, B.C., Jackson, K.M., Dwyer, B., Characterization of Mycobacterium tuberculosis strains from Vietnamese patients by Southern blot hybridization. J Clin Microbiol 31 (1993), 1615–1618.
8. 8. Sanker, S., Ramamuthy, M., Nandagopal, B., et al. An appraisal of PCR-based technology in the detection of Mycobacterium tuberculosis. Mol Diag Ther 15 (2011), 1–11.
9. 9. Ou, X., Li, Q., Xia, H., et al. Diagnostic accuracy of the PURE-LAMP Test for pulmonary tuberculosis at the county-level laboratory in China. PLoS One, 9, 2014, e74544.
10. 10. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva: WHO, 2014. WHO/HTM/TB/2013.16. http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf?ua=1.
11. 11. Centers for Disease Control. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR 58 (2009), 7–10.
12. 12. National Institute for Health and Care Excellence. Tuberculosis – clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: NICE, 2011. http://www.nice.org.uk/guidance/cg117/resources/guidance-tuberculosis-pdf.
13. 13. Hughes, R., Wonderling, D., Li, B., Higgins, B., The cost effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis. Respir Med 106 (2012), 300–307.
14. 14. Sohn, H., Aero, A.D., Menzies, D., et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 58 (2014), 970–976.
15. 15. Cepheid. Press release. Cepheid, FIND & Rutgers announce collaboration for next-generation innovations to game-changing Xpert MTB/RIF test. 28 Oct 2014, cited Nov 2014. http://www.finddiagnostics.org/resource-centre/press/141028.html.
16. th Union World Conference on Lung Health, Barcelona, 28 October-1 November 2014.
17. 17. Telenti, A., Imboden, P., Marchesi, F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993), 647–650.
18. 18. Valvatne, H., Syre, H., Kross, M., et al. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. J Antimicrob Chemother 64 (2009), 694–701.
19. 19. van Doorn, H.R., An, D.D., de Jong, M.D., et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 12 (2008), 736–742.
20. 20. Plinke, C., Rüsch-Gerdes, S., Niemann, S., Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 50 (2006), 1900–1902.
21. 21. Ahmad, S., Jaber, A.A., Mokaddas, E., Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 87 (2007), 123–129.
22. 22. Miotto, P., Cabibbe, A.M., Feuerriegel, S., et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio 5 (2014), e01819–e01824.
23. 23. World Health Organization. Xpert MTB/RIF implementation manual: technical and operational ‘how-to’; practical considerations. Geneva, WHO 2014. WHO/HTM/TB/2014.1. http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf.
24. 24. World Health Organization. Factsheet Tuberculosis Diagnostics Xpert MTB/RIF Test. Geneva: WHO, 2014. http://www.who.int/tb/publications/Xpert_factsheet.pdf?ua=1.
25. 25. Drobniewski, F., Nikolayevskyy, V., Balabanova, Y., et al. Diagnosis of tuberculosis and drug resistance: what can new tools bring us. Int J Tuberc Lung Dis 16 (2012), 860–870.
26. 26. World Health Organization. The use of molecular line probe assay for the detection of resistance to second line anti tuberculosis drugs - 2013 Expert Group Meeting Report, Geneva. Geneva: WHO, 2013. WHO/HTM/TB/ 2013.01 http://apps.who.int/iris/bitstream/10665/78099/1/WHO_HTM_TB_2013.01.eng.pdf.
27. 27. Hillemann, D., Rüsch-Gerdes, S., Richter, E., Feasibility of the GenoType MTBDRsl Assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 46 (2009), 1767–1772.
28. 28. Mitarai, S., Kato, S., Ogata, H., et al. Comprehensive multicenter evaluation of a new line probe assay kit for the identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 50 (2012), 884–890.
29. 29. Van Deun, A., Aung, K.J.M., Bola, V., et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51 (2013), 2633–2640.
30. 30. Rigouts, L., Mourad Gumusboga, A.B., Willem Bram de Rijk, A., et al. Rifampin resistance missed in automated liquid culture system for Myco-bacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51 (2013), 2641–2645.
31. 31. Williamson, D.A., Roberts, S.A., Bower, J.E., et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 16 (2011), 216–220.
32. 32. Yip, C.W., Leung, K.L., Wong, D., et al. Denaturing HPLC for high throughput screening of rifampicin- resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 10 (2006), 625–630.
33. 33. Chang, K.C., Yew, W.W., Zhang, Y., Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 55 (2011), 4499–4505.
34. 34. Didelot, X., Bowden, R., Wilson, D.J., et al. Transforming clinical microbiology with bacterial genome sequencing. Nat Genet Rev 13 (2012), 601–612.
35. 35. Walker, T.M., Ip, C.L.C., Harrell, R.H., et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13 (2013), 137–146.
36. 36. Ford, C.B., Lin, P.L., Chase, M.R., et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43 (2011), 482–486.
37. 37. Bryant, J.M., Schurch, A.C., van Deutekom, H., et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis, 13, 2013, 110.
38. 38. Gardy, J.L., Johnston, J.C., Ho Sui, S.J., et al. Whole-genome sequencing and social network analysis of a tuberculosis outbreak. N Engl J Med 364 (2011), 730–739.
39. 39. Jamieson, F.B., Teatero, S., Guthrie, J.L., et al. Whole-genome sequencingof the Mycobacterium tuberculosis Manila sublineage results in less clustering and better resolution than mycobacterial interspersed repetitive-unit–variable-number tandem repeat (MIRU-VNTR) typing and spoligotyping. J Clin Microbiol 52 (2014), 3795–3798.
40. 40. Casali, N., Nikolayevskyy, V., Balabanova, Y., et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46 (2014), 279–286.
41. 41. Sun, G., Luo, T., Yang, C., et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 206 (2012), 1724–1733.
42. 42. Kohl, T.A., Diel, R., Harmsen, D., et al. Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol 52 (2014), 2479–2486.
43. 43. Koser, C.U., Bryant, J.M., Becq, J., et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369 (2013), 290–292.
44. 44. Aviles, E., Requirements for managing “big data”: a global database of DR molecular sequence data. Int J Tuberc Lung Dis 18:Suppl 1 (2014), S48–S49.
45. 45. Zar, H., Udwadia, Z., Advances in tuberculosis 2011-2012. Thorax 68 (2013), 283–287.